文献速递糖尿病

利用随机试验个体参与者数据开发并验证2型糖尿病并发症风险方程(RECODe)

Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-08-10

研究利用ACCORD试验(n=9635)数据开发2型糖尿病并发症风险方程RECODe,并在DPPOS(n=1018)和Look AHEAD(n=4760)中验证。方程对微血管和心血管结局具有中等判别力和高度校准,优于UKPDS Outcomes Model 2和ACC/AHA Pooled Cohort Equations。

要点

  • RECODe方程覆盖肾病、视网膜病变、神经病变、心肌梗死、卒中、心力衰竭、心血管死亡和全因死亡。
  • 内部判别C统计量0·55-0·84,外部判别0·57-0·79;内部和外部校准斜率0·71-1·31。
  • RECODe的判别力和校准优于UKPDS Outcomes Model 2和ACC/AHA Pooled Cohort Equations。

核心结论

  • RECODe可能改善2型糖尿病患者并发症风险的估计。

研究设计与样本

  • 利用ACCORD研究(n=9635;2001-09)数据开发风险方程,微血管事件在DPPOS(n=1018;1996-2001)中验证,心血管事件在Look AHEAD(n=4760;2001-12)中验证。
  • 采用交叉验证机器学习方法从人口学特征、临床变量、合并症、药物和生物标志物中筛选预测变量,纳入各结局的Cox比例风险模型。

主要发现

  • 所有方程内部和外部判别力均为中等(内部C统计量0·55-0·84,外部0·57-0·79),内部和外部校准均高(观测与估计风险斜率0·71-1·31)。
  • 与UKPDS Outcomes Model 2相比,RECODe对微血管和心血管结局的判别力和校准更优(UKPDS Outcomes Model 2的C统计量0·54-0·62,斜率0·06-1·12)。
  • 与ACC/AHA Pooled Cohort Equations相比,RECODe对致死或非致死性心肌梗死或卒中的判别力和校准更优(Pooled Cohort Equations的C统计量0·61-0·66,斜率0·30-0·39)。

关键数值与推荐

  • 微血管结局包括肾病、视网膜病变和神经病变;心血管结局包括心肌梗死、卒中、充血性心力衰竭和心血管死亡;另纳入全因死亡为结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In view of substantial mis-estimation of risks of diabetes complications using existing equations, we sought to develop updated Risk Equations for Complications Of type 2 Diabetes (RECODe). METHODS: To develop and validate these risk equations, we used data from the Action to Control Cardiovascular Risk in Diabetes study (ACCORD, n=9635; 2001-09) and validated the equations for microvascular events using data from the Diabetes Prevention Program Outcomes Study (DPPOS, n=1018; 1996-2001), and for cardiovascular events using data from the Action for Health in Diabetes (Look AHEAD, n=4760; 2001-12). Microvascular outcomes were nephropathy, retinopathy, and neuropathy. Cardiovascular outcomes were myocardial infarction, stroke, congestive heart failure, and cardiovascular mortality. We also included all-cause mortality as an outcome. We used a cross-validating machine learning method to select predictor variables from demographic characteristics, clinical variables, comorbidities, medications, and biomarkers into Cox proportional hazards models for each outcome. The new equations were compared to older risk equations by assessing model discrimination, calibration, and the net reclassification index. FINDINGS: All equations had moderate internal and external discrimination (C-statistics 0·55-0·84 internally, 0·57-0·79 externally) and high internal and external calibration (slopes 0·71-1·31 between observed and estimated risk). Our equations had better discrimination and calibration than the UK Prospective Diabetes Study Outcomes Model 2 (for microvascular and cardiovascular outcomes, C-statistics 0·54-0·62, slopes 0·06-1·12) and the American College of Cardiology/American Heart Association Pooled Cohort Equations (for fatal or non-fatal myocardial infarction or stroke, C-statistics 0·61-0·66, slopes 0·30-0·39). INTERPRETATION: RECODe might improve estimation of risk of complications for patients with type 2 diabetes. FUNDING: National Institute for Diabetes and Digestive and Kidney Disease, National Heart, Lung and Blood Institute, and National Institute on Minority Health and Health Disparities, National Institutes of Health, and US Department of Veterans Affairs.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Basu S, Sussman JB, Berkowitz SA, et al. Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017. PMID: 28803840. doi:10.1016/S2213-8587(17)30221-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。